Toripalimab Combined With CAV/IE Regimen

The aim of this study was to investigate the efficacy and safety of CAV/IE chemotherapy combined with toripalimab versus CAV/IE chemotherapy alone in the treatment of patients with advanced or unresectable bone and soft tissue sarcomas who failed in standard treatment.

Trial Details

NCT ID
NCT04589741
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Toripalimab Combined With CAV/IE chemotherapy
  • CAV/IE alternate chemotherapy
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Patients voluntarily participated in the study and signed informed consent;
  • For all advanced or non resectable bone and soft tissue sarcomas confirmed by pathology, the standard treatment failed or there was no standard tre…
  • Advanced patients with unresectable lesions or lymph nodes or distant metastasis assessed by imaging;
  • In the past three months, there was at least one measurable target lesion according to RECIST version 1.1 standard, and it can be accurately measur…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →